Search Bar & Filters
Found 10 Actively Recruiting clinical trials
Actively Recruiting
Researchers are studying the effects of a nutritional intervention combining ketogenic medium-chain triglycerides kMCT and B-vitamins on cognitive function in older adults diagnosed with mild cognitive impairment MCI. This randomized, double-blind, placebo-controlled trial aims to evaluate how this nutritional approach impacts cognitive performance over a 12-month period. The study is sponsored by Socit des Produits Nestl and involves multiple centers and countries. Participants will be randomly assigned to receive either BrainXpert, a dietary supplement containing 15 g of kMCT and B-vitamins in powder form, or a placebo consisting of a calorie-equivalent, non-ketogenic high-oleic acid sunflower oil powder. Both are provided in sachetstickpack format without preservatives, flavors, sweeteners, or colorants. The intervention is administered daily during the study period. During the trial, participants and their informants will attend clinic visits at baseline, 12 months, and 18 months. Cognitive function will be assessed using tools such as the Preclinical Alzheimers Cognitive Composite PACC, Montreal Cognitive Assessment MoCA, Wechsler Memory Scale, and Mini-Mental State Examination MMSE. Safety and tolerability will also be monitored throughout the 12 months. The study includes adherence assessments and requires participants to comply with study procedures and medication restrictions.
Actively Recruiting
This research aims to determine whether performing an extended pelvic lymph node dissection ePLND during radical prostatectomy benefits men with high-risk prostate cancer. The study investigates if ePLND improves cancer staging and removes undetectable cancer cells that standard imaging techniques like PSMA-PET might miss, potentially leading to better treatment outcomes. The trial is a multicenter, randomized phase III study sponsored by University Hospital, Basel, Switzerland. Participants will be randomly assigned to one of two groups radical prostatectomy with extended pelvic lymph node dissection or radical prostatectomy without the extended lymph node dissection. Extended PLND involves removing more lymph nodes than the standard procedure, aiming for better detection of cancer spread. The study compares outcomes between these two approaches, while considering surgery time and complication risks, which may be slightly higher with ePLND. During the study, participants will be monitored over a long-term period of up to 10 to 15 years. Researchers will measure prostate-specific antigen PSA persistence about 3 months after surgery and track biochemical recurrence-free survival within 24 months. Secondary measures include time to recurrence, metastasis, survival rates, complications, adverse events related to ePLND, and patient-reported outcomes. This comprehensive follow-up includes assessments during surgery, postoperatively, and over many years to evaluate the overall impact of the surgical approaches.
Actively Recruiting
This research aims to compare different types of rods used in the surgical treatment of degenerative lumbar spine diseases. The study focuses on patients with degenerative symptoms in one or two segments of the lumbar spine from L1 to S1. It seeks to determine whether the use of high-flex elastic or mid-flex medium rods provides clinical and safety outcomes that are not inferior to those achieved with low-flex stiff rods, with a special focus on reducing back pain and improving functionality after surgery. Participants will be randomly assigned to receive one of three types of SpineShape System IV rods elastic high-flex, medium mid-flex, or stiff low-flex. Each group will undergo dynamic stabilization surgery using the assigned rod type. The study will follow patients over five years, with evaluations occurring before surgery and at 3, 12, 24, and 60 months after implantation to assess pain levels, mobility, medication use, and other health indicators. During the study, participants will complete questionnaires and undergo clinical assessments to measure back and leg pain using the Visual Analogue Scale VAS, walking duration, medication consumption, and segmental mobility. Researchers will also monitor adverse events and participants ability to work or perform activities. The total participation spans at least five years, with regular follow-up visits to collect data on safety and treatment outcomes.
Actively Recruiting
Healthy Volunteer
Researchers are studying nerve excitation sensitivity in healthy volunteers to understand how different methods of peripheral nerve stimulation affect nerve activation. This study evaluates electric, electromagnetic, and temporal interference stimulations in the upper arm, focusing on the relationship between nerve activation and coil placement as well as how various coil types influence maximal nerve response. Participants will receive momentary, non-therapeutic electric and electromagnetic stimulations using different coil designs and electrodes. These stimulations are applied to assess peripheral nerve sensitivity during a single study day. The study measures maximum nerve activation response with different coils and evaluates the spatial range of nerve activation and amplitude ratios associated with nerve stimulation. During the study, volunteers will undergo various stimulations of the upper arm nerves. Researchers will monitor nerve activation using different coils and electrodes, and collect data on responses to these stimulations. The primary outcome is the maximal activation response to electromagnetic stimulation, with secondary outcomes including spatial activation ranges and amplitude ratios. Participants need to be healthy and able to follow study procedures, with total involvement lasting one day.
Actively Recruiting
Researchers are studying primary and acquired resistance mechanisms to standard treatments targeting BRAF V600E mutations in metastatic colorectal cancer. This observational study focuses on patients receiving combined therapy with BRAF inhibitor encorafenib, anti-EGFR antibody cetuximab, and chemotherapy. Resistance to this combination often develops, limiting treatment options, so the study aims to uncover genetic and non-genetic reasons behind this resistance to help develop better future therapies. Participants will receive standard-of-care treatment with encorafenib, cetuximab, and possibly chemotherapy. Before starting treatment and at the time of disease progression, researchers will collect tumor tissue, blood, and stool samples. These samples will be used to study molecular changes and the microbiome, and to create patient-derived organoids for laboratory testing. Blood samples will be collected regularly during treatment to analyze circulating tumor DNA over time. Throughout the study, participants will be followed longitudinally with sample collections before treatment and at progression, continuing for up to around 24 months. Researchers will measure molecular alterations linked to resistance, compare tissue and liquid biopsy findings, characterize gut microbiome changes, and track tumor DNA dynamics. The studys findings aim to improve understanding of resistance and support personalized treatment approaches for metastatic colorectal cancer.
Actively Recruiting
This research aims to collect and analyze a wide range of information from patients with urologic diseases, including uro-oncological and other urological conditions, who receive care at the study sites. The goal is to use advanced neural networks to identify important clinical outcomes by studying a large sample of these patients over time. This observational study is sponsored by Insel Gruppe AG, University Hospital Bern. Participants will receive standard care tailored to their specific urological conditions without any experimental treatments. The study will gather and store detailed patient data in layered databases for analysis. This approach allows researchers to observe real-world treatment effects and patient outcomes without interfering with usual medical care. During the study, participants medical histories and clinical information will be recorded and monitored over 4 to 5 years to evaluate disease-specific primary outcomes. As an observational study, there are no additional interventions or treatments beyond regular care. The study mainly focuses on collecting data to improve understanding and measurement of quality and outcomes in urological patient care.
Actively Recruiting
Researchers are studying patients with non-metastatic, mismatch repair-deficient MMRd or microsatellite instability-high MSI-H gastrointestinal cancers, including colorectal cancer, to evaluate management strategies after immunotherapy. The study has two parts Part A is an observational registry of patients treated with surgery andor immunotherapy, while Part B is a phase II surveillance study for patients showing complete or near-complete response to immune checkpoint inhibitors ICI who wish to avoid surgery. This research aims to understand the safety and outcomes of non-operative management in these patients. Eligible patients receive immune checkpoint inhibitor therapy, such as PD-L1 monotherapy or combination therapy, for up to 6 months or longer if near-complete response occurs. Patients not achieving complete response or unwilling for non-operative management proceed to standard surgery and follow routine follow-up Part A. Those with complete or near-complete response enter an active surveillance program Part B involving clinical assessments, imaging CT or MRI, endoscopy, and optional circulating tumor DNA testing after immunotherapy. Participants undergo regular evaluations including imaging and endoscopy during surveillance to monitor for cancer relapse. The primary outcome is 2-year relapse-free survival in the surveillance group. Patients in the registry are followed according to institutional standards. The study spans several years, with long-term monitoring to assess relapse and response. This approach aims to improve quality of life by potentially avoiding surgery when safely possible.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of intravenous thrombolysis IVT in adults who have had an acute ischemic stroke AIS and recently taken direct oral anticoagulants DOACs within the last 48 hours. This international, multicenter, randomized study aims to determine whether IVT combined with standard medical care leads to better outcomes at 90 days compared to standard care alone. The trial is designed as a phase 4 superiority study enrolling 906 participants at several high-volume stroke centers worldwide. Participants will be randomly assigned to one of two groups one group will receive intravenous thrombolysis using Tenecteplase or Alteplase along with the best standard medical treatment, while the other group will receive only the standard of care as per local and international guidelines. Treatment must begin within specific time windows based on stroke onset or MRI findings. The study follows current guidelines from major stroke organizations, ensuring participants receive appropriate care. During the study, participants will be monitored and assessed using the Modified Rankin Scale at 90 days to evaluate functional outcomes. Additional measures include stroke severity changes assessed by the NIH Stroke Scale within 24 hours, and quality of life questionnaires at 90 days. The study includes careful safety monitoring and long-term follow-up to fully assess treatment effects and participant well-being throughout and after the 90-day period.
Actively Recruiting
Researchers are investigating how a structured shared decision making SDM approach affects patient-centered outcomes for those choosing between surgical aortic valve replacement SAVR and transcatheter aortic valve replacement TAVR. This trial focuses on patients aged 70 and older with symptomatic severe aortic stenosis, where both SAVR and TAVR are considered appropriate treatment options. The study compares the effects of SDM to usual care in helping patients make informed treatment choices. Participants are randomly assigned to one of two groups one receives a structured SDM conversation with a heart team member using an adapted three-talk model and decision aids, while the other group receives usual care involving at least one decision-making discussion without the structured approach. The trial is open-label and single-center, enrolling 140 patients to assess how these approaches influence decision quality and satisfaction. Throughout the study, patients complete assessments shortly after baseline visits and again at 30 days and one year following their valve replacement. These evaluations measure decisional conflict, regret, communication quality, knowledge about treatment options, satisfaction, incorporation of patient values, and health-related quality of life. Safety is monitored by tracking major adverse events after treatment. The study aims to improve understanding of patient experiences and decision-making in heart valve replacement over a multi-year period.
Actively Recruiting
Researchers are collecting detailed information about people with cerebral palsy CP in Switzerland through the Swiss-CP-Reg, a national patient registry started in 2017. This registry gathers data on diagnosis, symptoms, treatments, and follow-up care for children, adolescents, and adults with CP. The goal is to better understand CPs prevalence, risk factors, clinical profiles, and needs, ultimately aiming to improve treatment and quality of life. The registry involves multiple Swiss clinics and medical practices and invites all people diagnosed with CP who were born, treated, or live in Switzerland to participate. Data collected include medical records, questionnaires for patients and families, and links to routine statistics and medical registries. Follow-up data are gathered regularly at diagnosis, ages 5, 10, 15, and at the transition to adult care around age 18. The registry also supports clinical research and international collaboration to enhance knowledge exchange and therapeutic approaches. Participants provide informed consent and are followed over time with regular updates on their medical status, motor function, comorbidities, treatments, and quality of life. The registry collects comprehensive information such as birth history, diagnosis details, therapies, surgeries, and socio-economic factors. Data collection includes questionnaires on health, education, and social participation. The study continually analyzes and publishes findings to support better care for people with CP in Switzerland.